Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (82)

Lopez-Pintor E (1), Valenzuela B (1), Montesinos A (2), Martín-Villodre A (2), Casabó V.G (2)

Population pharmacokinetics approach for salbutamol sulphate in rats

Tousset, E.(1), H. Figueiredo (2),M.P. Schneider(2),O. Bugnon(2), B.Vrijens (1)

Relation between patients’ variable compliance and office blood pressure in treatment-resistant hypertension.

Marshall, Scott1, Mike K Smith1, Eugene Cox2,3 and Jaap Mandema2,4

Application of PK/PD modelling in the development eletriptan DR for the treatment of acute migraine and prevention of headache recurrence.

Hempel, Georg; Lanvers-Kaminsky, Claudia; Ahlke, Elvira; Müller, Hans-J.; Würthwein, Gudrun; Boos, Joachim

A Population Model Describing the Activity-time Course of Pegylated Asparaginase in Children

Claret, L. (1), P. Girard (2), K.P. Zuideveld(3), K. Jorga (3), J. Fagerberg (3), R. Bruno (1)

A longitudinal model for tumor size measurements in clinical oncology studies

Paccaly, A (1), Speth, H (2), Jensen, BK (1), Maas, J (2)

Non-Linear Population Pharmacokinetic Model for Otamixaban in Healthy Male Subjects

Roy Pierre, Annabelle Lemenuel-Diot, Marylore Chenel

Is it possible to perform equivalent simulations with NONMEM and TS2?

Olofsen, E.

Using the Lasso to simultaneously identify the covariate and variance-covariance structures of nonlinear mixed-effects models

Lindbom, Lars(1), Justin J Wilkins(1), Nicolas Frey(2), Mats O Karlsson(1), E Niclas Jonsson(1,2)

Evaluating the evaluations: resampling methods for determining model appropriateness in pharmacometric data analysis

Ortega, Ignacio , An Vermeulen, Vladimir Piotrovsky

Concentration-response analysis of antipsychotic drug effects using an indirect response model

Edginton, A.N. (1), S. Willmann (1), M. Kleine-Besten (2)

Use of a physiology-based whole-body population model to simulate the influence of anthropometric-, clearance-, and physiological-variance on the pharmacokinetics of drugs

Comets, Emmanuelle(1) and Céline Verstuyft (2)

Analysis of digoxin data using Non-Parametric Maximum Likelihood (NPML)

Holford, Nick, Carl Kirkpatrick, Steve Duffull

NONMEM Termination Status is Not an Important Indicator of the Quality of Bootstrap Parameter Estimates

Bertrand, Julie, Emmanuelle Comets, France Mentré

Detecting a gene effect in pharmacokinetic models: comparison of different methods

Zeumer, D., A. Staab, T. Lehr, C. Tillmann, K.-H. Liesenfeld, H. G. Schaefer

PROPHET – A convenient and efficient environment for the use of NONMEM in a global pharmaceutical company

Dehez, Marion(1)(2)(3), Marylore Chenel(1), Roeline Jochemsen(1), Stéphanie Ragot(2)

Population modeling approach of circadian blood pressure variations using ambulatory monitoring in dippers and non dippers

Valle M, Grasa E, Yritia M, Romero S,, Barbanoj MJ.

Population Pharmacokinetic-Pharmacodynamic modelling of olanzapine effects on the electroencephalogram in healthy volunteers.

Lehr, T.(1), A. Staab (2), C. Tillmann (2), D.Trommeshauser (2), A. Raschig(2), H.G. Schaefer (2), C. Kloft (1,3)

Population pharmacokinetics of NS2330 and its major metabolite in Alzheimer’s disease patients

Lehr, T. (1), A. Staab (2), C. Tillmann (2), D. Trommeshauser (2), A. Raschig (2), H.G. Schaefer (2), C. Kloft (1,3)

Efficacy modelling of NS2330 in mild Alzheimer’s disease patients

Dittberner, S.(1), V. Duval (2), A. Staab (2), H. Fuchs (2), M. Tadayyon (2), U. Graefe-Mody (2), H.G. Schaefer (2), U. Jaehde (1)

Pre-Clinical PK/PD Modeling for a Dipeptidyl Peptidase-IV Inhibitor

Chantel, S.(1,2), P. Martin(1,2), P.Y. Petit (3), D. Massignon(4), X. Dode(1), P. Maire (5), R.W. Jelliffe(6), G. Aulagner(1,2)

Pharmacokinetic variability of the absorption of enoxaparin used subcutaneously for venous thromboembolism prophylaxis

Quartino, Angelica L., Lena E. Friberg, Mats O. Karlsson

A simultaneous analysis of the time course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic model

Hussein, Ziad(1), Brigitte Lacroix(2), Maria-Laura Sargentini-Maier(2)

Population pharmacokinetics of the new antiepileptic drug brivaracetam

Nielsen, Elisabet I(1), Uwe Ewald (2), Lena E Friberg (1)

Population Pharmacokinetics of Gentamicin in Preterm and Term Newborn Infants

Wilkins, Justin J (1), Karlsson, Mats O (1), Jonsson, E Niclas (2)

Patterns and power for the visual predictive check

Nekka, Fahima (1,2), Caroline-E. Petit-jetté (1), Jun Li (1,2), Denis Gohore Bi (1), Renée Bergeron (3), Jérome del Castillo (4)

Therapeutic modelling and analysis of random feeding features of feed-administered chlortetracycline

Weatherley B., L. McFadyen, P. Milligan

Population Analysis of Maraviroc Phase 1 Noncompartmental Pharmacokinetic Data

Nalda-Molina, R (1), Bermejo M. (2), Casabó V.G. (2)

A simple physiological-pharmacokinetic model to simulate bioequivalence trials

Ramón-López A. (1), Nalda-Molina R. (1), Valenzuela B. (1), Pérez Ruixo J.J.(1), Jiménez Torres N.V.(2),

Semi-mechanistic KPD model for haematological toxicity in breast cancer patients receiving high dose of chemotherapy

Perez Ruixo, Juan Jose

Optimizing the Design of Phase I Studies of Erythropoietin Receptor Agonist Through Mechanism-Based PK/PD Modeling and Simulation

Dodds, M.G. (1), J.E. Visich(1), I. Nestorov(1), R. Overgaard(2), M.C. Rogge(1)

Population pharmacodynamic model of the effects of recombinant human interleukin 21 on platelets in humans

Leary, Robert H. and Dunlavey, Michael

Parallel Processing for Nonlinear Mixed Effects Modeling

Gupta, M, K Wade, B Jayaraman, J Mondick, JS Barrett

Optimizing Fluconazole Dosing in Preterm Neonates Based on Simulations from Posterior Parameter (Uncertainty) Distributions

Hing, Jeremy(1), Juan Jose Perez-Ruixo(1), Kim Stuyckens(1), Peter Zannikos(1), Arturo Soto-Matos(2), César Picó(2), Antoine Yver(1) and Andrew Chow(1)

Population PK/PD Modelling & Simulation of Hematological Toxicity of Trabectedin in Cancer Subjects

Hutmacher, Matthew M, Sriram Krishnaswami

An extension of the indirect response models to ordered categorical pharmacodynamic data using latent variables

Nestorov, I.1, A. Munafo2, O. Papasouliotis2, J. Visich1 and M. Rogge1

Population modeling of the relationship between TACI Ig exposure and biomarker response in patients with rheumatoid arthritis (RA)

Holford, Nick, Goonaseelan (Colin) Pillai, Nitin Kaila, William Collins, Sandip Roy, Serge Cremers, Ulrich Trechsel, Florilene Bouisset, Jean-Louis Steimer

PKPD model for cathepsin K inhibition with balicatib and changes in bone turnover biomarkers, in particular NTx

Holford, Nick, Goonaseelan (Colin) Pillai, Sandip Roy, Andrej Skerjanec, Serge Cremers, William Collins, Jean-Louis Steimer

Population pharmacokinetics of balicatib, a cathepsin K inhibitor

Fernández-Teruel C, Navarro-Fontestad MC, González-Álvarez I, Bermejo M, Casabo VG

Sparse sampling designs: a new method for estimating the complete AUC and its standard error

Armendariz Y2, Caldes A2 , Colom H1, Gilvernet S2, Peraire C1, Domenech J1, Grinyó JM2, Wilkins J3, Karlsson M3.

Population pharmacokinetics of Valganciclovir in solid organ transplant recipients infected by cytomegalovirus

Prémaud, A(1), Van Guilder M (2), Armstrong VW (3), Weber LT(3), Ghandi A (2), Oellerich M (3), Tonshoff B (3), Jelliffe R (2), Marquet P (1), Rousseau A (1)

Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in paediatric renal transplant recipients using a non-parametric approach.

Matthews, Ivan (1), Smith, Fang Gao (2), Aarons, Leon (1)

Pharmacokinetics of a single bolus of propofol in Chinese children of different ages

Gaynor, Clare (1), Dunne, Adrian (1) and Davis, John (2)

Comparison of conventional In Vitro – In Vivo Correlation methodology with non-linear mixed effects modelling

Prins, K (1), B. Poland (1), V. Nicolas (2), H. Porchet (2), P. Scalfaro (2), R. Bruno (1)

Modeling and Simulation of DEBIO-025 to Support Design of a Dose-Response Monotherapy Study in HIV-1 infected Patients

Panhard, Xavière and Adeline Samson

Extension of the SAEM algorithm for the estimation of Inter-Occasion Variability: application to the population pharmacokinetics of nelfinavir and its metabolite M8

Al Za’abi MA (1), Xiaonian X (2), Donovan T (3), Charles BG (1)

Use of Routine Data for Determination of the Population Pharmacokinetics and Enteral Bioavailability of Phenytoin in Neonates and Infants with Seizures

Marchand, M. (1), O. Petricoul (1), E. Fuseau (1), D. Bentley (2), D. Critchley (2)

Extrapolation from preclinical PKPD data to clinical response, Application to a new antiepileptic medication (drug X)

Mills, Richard (1,2), Kayode Ogungbenro (1) & Leon Aarons (1)

Simultaneous fitting of the Minimal Model to IVGTT and Glucose Clamp Data

Duffull, S B (1), G Graham (2), K Mengersen (3)

Bayesian Estimation of Optimal Sampling Times for Pharmacokinetic Models

Miller, Raymond , Howard Bockbrader, Sunny Chapel.

Comparision of Pregabalin and Gabapentin Pharmacodynamics in Patients with Refractory Partial Seizures.

Friberg, Lena E.(1), An M. Vermeulen(2), Mats O. Karlsson(1)

A mechanism-based pharmacokinetic-pharmacodynamic model of the time-course of prolactin following antipsychotic drug treatment

Testart, D.(1), G. Blanc(2), P. Delrat(1), T. Shepard(1)

Development of a tool to simulate intra-individual variability encountered in animals from standard preclinical toxicological study

Langdon G (1), Gueorguieva I (2), Aarons L (3), Karlsson MO (1)

Linking preclinical and clinical whole body physiologically-based pharmacokinetic models with prior distributions in NONMEM

Verbeke, Geert

Mixed models for the analysis of categorical repeated measures

van Hest, Reinier1, Teun van Gelder1,2, Arnold Vulto1, Leslie Shaw3, Ron Mathôt1

Pharmacokinetic modeling of plasma protein binding of mycophenolic acid in renal transplant recipients

Tajima, Takeshi(1), Akihiro Yokoi (1), Peiming Ma (2), Ryosei Kawai (1)

Population approach to assess the relationship of cyclosporin exposure and renal dysfunction in Japanese patients with rheumatoid arthritis

Joerger, M., A.D.R. Huitema, V. D. Doodeman, H. Boot, R. W. Sparidans, J.H. Beijnen, J.H.M. Schellens

Epirubicin pharmacokinetics-pharmacodynamics and metabolic pathway-associated gene polymorphisms: Significant influence of the novel UDP-glucuronosyltransferase 2B7 promoter mutation -66T>C

Yim, Dong-Seok (1), Dong-Gun Lee, Su-Mi Choi, Wan-Shik Shin, Hyon-oh Lah(1)

Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea

William Faltaos, D (1), S. Urien (1), V.Morel (2), G. Kaloshi (3), k. Hoang Xuan (3), V.Leblond (2), Philippe Lechat (1).

Population pharmacokinetic study of methotrexate in patient with lymphoid malignancy

Zandvliet, Anthe S.(1), Alwin D.R. Huitema (1), William Copalu (2), Yasuhide Yamada (3), Tomohide Tamura (3), Jos H. Beijnen (1,4) , Jan H.M. Schellens (4,5)

Pharmacogenetically guided dosing of the anticancer agent indisulam normalizes the risk of severe hematological toxicity

Plock, N.(1), C. Buerger(1), K. Kuester(1), C. Joukhadar(2), S. Kljucar(3), C. Kloft(1,4)

A Population Pharmacokinetic Model for the Simultaneous Description of Linezolid Tissue and Plasma Disposition in Healthy Volunteers and Septic Patients

Hennig, S. (1,2), Waterhouse T.(1) Wainwright C.(3), Bell S.(4), Miller H. (2), Charles B.(1) and Duffull S.(1)

A D-optimal designed population pharmacokinetic study of itraconazole capsules and solution in adults with cystic fibrosis

Wallin, Johan E, Friberg Lena E., Karlsson Mats O.

An Adaptive Dosing Tool For Etoposide Using Neutrophil Counts Based on a Semi-Physiological Model

Lovern, Mark R , Ginny Schmith, George Dukes, David McSorley

Using a Placebo Response Model to Optimize Clinical Trial Designs for Irritable Bowel Syndrome (IBS) Therapies

Djebli, Nassim 1, Pierre Marquet1,2, Yann Le Meur1,3, Annick Rousseau1,4

Population pharmacokinetics of sirolimus in adult renal transplant patients and Bayesian estimation of individual systemic exposure

Matthews, Ivan and Aarons, Leon